Tulane surgeon Dr. Shauna Levy says Louisiana insurers cover surgery more often than GLP-1s, and argues surgery costs less over a lifetime.
Recap by typeshit. Full story at www.investigatetv.com.
A retrospective study in Cureus looks back at how well once-weekly semaglutide worked, and how safe it was, for teenagers with obesity.
Presented at Sleep Europe 2026, both trials found retatrutide lowered the apnea-hypopnea index more than placebo, including in people with type 2 diabetes.
Endpoints News
Endpoints reports Eli Lilly is building a case for its triple agonist beyond obesity, where a launch is expected next year, with sleep apnea next in line.
Observational data link GLP-1 drugs to fewer cases of some cancers, but trials have yet to show they prevent cancer or help survival after a diagnosis.
A JAMA Network Surgery study tracks the shift, but Tulane surgeon Shauna Levy says Louisiana insurers cover surgery more often than GLP-1s.
GLP-1 prescriptions rose 24% from 2018 to 2025 as surgery fell. Tulane's Dr. Shauna Levy says Louisiana insurers cover surgery more often than the drugs.
Loading…